期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

晚期肿瘤患者异体肿瘤疫苗接种治疗的护理 被引量：2

晚期肿瘤患者异体肿瘤疫苗接种治疗的护理
下载PDF
导出
摘要 疫苗在抗微生物免疫中取得的巨大成功，使得人们开始考虑是否可以用同样的思路来治疗肿瘤。肿瘤疫苗治疗作为安全、不良反应小的肿瘤生物治疗方法，在增强化疗、放疗的效果，延长患者生存时间、改善生活质量等方面展示了可喜的前景。有临床研究^[1]认为，表达GMCSF的肿瘤细胞疫苗是这一策略较好的选择。
作者 王艳 刘佳
机构地区 天津医科大学附属肿瘤医院
出处 《护士进修杂志》 2012年第9期819-820,共2页 Journal of Nurses Training
关键词 异体肿瘤疫苗 护理 Allogeneic tumor vaccine Nursing
分类号 R473.73 [医药卫生—护理学] R73-352 [医药卫生—肿瘤]
  • 相关文献

参考文献2

二级参考文献12

  • 1[1]Tani K,Azuma M,Nakazaki Y,et al.Phase Ⅰ study of autologous tumor vaccines transduced with the GM-CSF gene in four patients with stageⅣ renal cell cancer in Japan:clinical and immunological findings.Mol Ther,2004,10(4):799-816.
  • 2[2]Soiffer R,Hodi FS,Haluska F,et al.Vaccination with irradiated,autologous melanoma cells engineered to secrete granulocytemacrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma.J Clin Oncol,2003,21(17):3343-3350.
  • 3[3]Nemunaitis J,Jahan T,Ross H,et al.Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX vaccine in advanced-stage non-small-cell lung cancer.Cancer Gene Ther,2006,13(6):555-562.
  • 4[4]Jaffee EM,Hruban RH,Biedrzycki B,et al.Novel allogeneic granulocyte-macrophagu colony-stimulating factor-secreting tumor vaccine for pancreatic cancer:a phase 1 trial of safety and immune activation.J Clin Oncol,2001,19(1):145-156.
  • 5[5]Small EJ,Sacks N,Nemunaitis J,et al.Cnranulocyte macrophage colony-stimulating factor-secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer.Clin Cancer Res,2007,13(13):3883-3891.
  • 6[6]Thomas AM,Santarsiero LM,Lutz ER,et al.Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients.J Exp Meal,2004,200(3):297-306.
  • 7[7]Bubley GJ,Carducci M,Dahut W,et al.Eligibility and response guidelines for phase Ⅱ clinical trials in androgen-independent prostate cancer:recommendations from the Prostate-Specific Antigen Working Group.J Clin Oncol,1999,17(11)3461-3467.
  • 8[8]Salgia R,Lynch T,Skarin A,et al.Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitamor immunity in some patients with metastatic non-small-cell lung carcinoma.J Clin Oncol,2003,21(4):624-630.
  • 9[9]Soiffer R,Hodi FS,Haluska F,et al.Vaccination with irradiated,autologous melanoma cells engineered to secrete granulocytemacrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma.J Clin Oncol,2003,21(17):3343-3350.
  • 10[10]Nemanaltis J,Sterman D,Jablons D,et al.Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer.J Natl Cancer Ⅰ,2004,96(4):326-331.

共引文献7

同被引文献47

  • 1杨化强,曹以诚.细胞因子和趋化因子作为DNA疫苗基因佐剂的研究进展[J].中南药学,2006,4(1):39-42. 被引量：1
  • 2Cheever MA,Higano CS. PROVENGE (Sipuleucel-T) in prostate cancer:the first FDA-approved therapeutic cancer vaccine[J].Clinical Cancer Research,2011,(11):3520-3526.
  • 3Riedmann EM. Two years of Provenge[J].Hum Vaccin Immunother,2012,(04):505.
  • 4Madan RA,Gulley JL. Sipuleucel-T:harbinger of a new age of therapeutics for prostate cancer[J].Expert Review of Vaccines,2011,(02):141-150.
  • 5Parmiani G,Castelli C,Pilla L. Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients[J].Annals of Oncology,2007,(02):226-232.
  • 6Olivares J,Kumar P,Yu Y. Phase Ⅰ trial of TGF-beta 2 antisense GM-CSF gene-modified autologous tumor cell (TAG) vaccine[J].Clinical Cancer Research,2011,(01):183-192.
  • 7Okada H,Lieberman FS,Walter KA. Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas[J].Journal of Traditional Medicines,2007,(19):67-77.
  • 8Slingluff CJ. The present and future of peptide vaccines for cancer:single or multiple,long or short,alone or in combination[J].Cancer Journal,2011,(05):343-350.
  • 9Becker JC,Andersen MH,Hofmeister-Muller V. Survivinspecific T-cell reactivity correlates with tumor response and patient survival:a phase-Ⅱ peptide vaccination trial in metastatic melanoma[J].Cancer Immunology, Immunotherapy,2012,(11):2091-2103.
  • 10Schwartzentruber DJ,Lawson DH,Richards JM. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma[J].New England Journal of Medicine,2011,(22):2119-2127.

引证文献2

二级引证文献13

护士进修杂志
2012年 第9期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部